TEVA COPAXONE SHOWS REDUCTION IN EXACERBATIONS OF RELAPSING-REMITTING MULTIPLE SCLEROSIS, FDA CMTE. AGREES; PROGRESSION, ASSESSMENT STUDIES ADVISED
Executive Summary
Teva's Copaxone is effective in reducing exacerbations in patients with relapsing-remitting multiple sclerosis, FDA's Peripheral & Central Nervous System Drugs Advisory Committee agreed Sept. 19.